Trends in Stomach Cancer Burden in China: A Joinpoint and APC Analysis Based on GBD 2021.
1/5 보강
[BACKGROUND AND AIM] To study the corresponding strategies to control stomach cancer, a comprehensive assessment of the disease burden is required.
APA
Xie X, Su J, et al. (2025). Trends in Stomach Cancer Burden in China: A Joinpoint and APC Analysis Based on GBD 2021.. Journal of gastroenterology and hepatology, 40(6), 1500-1514. https://doi.org/10.1111/jgh.16956
MLA
Xie X, et al.. "Trends in Stomach Cancer Burden in China: A Joinpoint and APC Analysis Based on GBD 2021.." Journal of gastroenterology and hepatology, vol. 40, no. 6, 2025, pp. 1500-1514.
PMID
40166947 ↗
Abstract 한글 요약
[BACKGROUND AND AIM] To study the corresponding strategies to control stomach cancer, a comprehensive assessment of the disease burden is required. Herein, we present long-term trends in the burden of stomach cancer in China over the past three decades, as well as its epidemiological features.
[METHODS] We characterized the burden of stomach cancer in China using the GBD 2021 methods and results, based on prevalence, incidence, mortality, years of life lost (YLLs), years lived with disability (YLDs), and disability-adjusted life years (DALYs) estimated using the DisMod-MR 2-1. We also used joinpoint and age-period-cohort (APC) analysis methods to interpret the epidemiological characteristics of stomach cancer, project the disease burden of stomach cancer in China over the next decade, and compare these trends with global prevalence patterns.
[RESULTS] The age-standardized incidence (ASIR) and mortality rates (ASMR) in both sexes changed from 48.03 (40.21, 56.69) to 29.05 (22.42, 36.2) and from 46.05 (38.88, 54.43) to 21.51 (16.66, 26.61) per 100 000 people in China from 1990 to 2021. The age-standardized DALY rate in China decreased from 1181.61 (978.38, 1390.89) per 100 000 people in 1990 to 501.26 (387.29, 627.98) per 100 000 people in 2021. The average annual percentage change (AAPC) in age-standardized incidence, prevalence, and mortality rates for stomach cancer in China were -1.61 (95% CI: -1.73, -1.48), -0.50 (95% CI: -0.67, -0.32), and -2.44 (95% CI: -2.62, -2.26). The effects of age, period, and cohort on mortality rates differed.
[CONCLUSIONS] In the next decade, China's ASIR and ASMR for stomach cancer will continue to decline. However, despite the decrease in incidence, the overall burden of stomach cancer in China will remain significantly higher than the global average. The burden of stomach cancer in China will be a major public health challenge, given the country's large population base and aging population.
[METHODS] We characterized the burden of stomach cancer in China using the GBD 2021 methods and results, based on prevalence, incidence, mortality, years of life lost (YLLs), years lived with disability (YLDs), and disability-adjusted life years (DALYs) estimated using the DisMod-MR 2-1. We also used joinpoint and age-period-cohort (APC) analysis methods to interpret the epidemiological characteristics of stomach cancer, project the disease burden of stomach cancer in China over the next decade, and compare these trends with global prevalence patterns.
[RESULTS] The age-standardized incidence (ASIR) and mortality rates (ASMR) in both sexes changed from 48.03 (40.21, 56.69) to 29.05 (22.42, 36.2) and from 46.05 (38.88, 54.43) to 21.51 (16.66, 26.61) per 100 000 people in China from 1990 to 2021. The age-standardized DALY rate in China decreased from 1181.61 (978.38, 1390.89) per 100 000 people in 1990 to 501.26 (387.29, 627.98) per 100 000 people in 2021. The average annual percentage change (AAPC) in age-standardized incidence, prevalence, and mortality rates for stomach cancer in China were -1.61 (95% CI: -1.73, -1.48), -0.50 (95% CI: -0.67, -0.32), and -2.44 (95% CI: -2.62, -2.26). The effects of age, period, and cohort on mortality rates differed.
[CONCLUSIONS] In the next decade, China's ASIR and ASMR for stomach cancer will continue to decline. However, despite the decrease in incidence, the overall burden of stomach cancer in China will remain significantly higher than the global average. The burden of stomach cancer in China will be a major public health challenge, given the country's large population base and aging population.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- ATR inhibition potentiates the antitumor efficacy of HER3-DXd in HER3-positive/HR-positive breast cancer by increasing DNA damage.
- Promotion of hepatocellular carcinoma by small nuclear ribonucleoprotein polypeptide F through upregulation of transmembrane P24 trafficking protein 2 and triggering of the cGAS-STING pathway.
- Inhibition of LSD1 enhances T cells anti-tumor immunity by promoting TNFSF14 expression in gastric cancer.
- [Clinical Characteristics and Risk Factors of Human Cytomegalovirus Infection after Allogeneic Hematopoietic Stem Cell Transplantation in Children with Acute Myeloid Leukemia].
- FKBP10 as a prognostic biomarker and therapeutic target in hepatocellular carcinoma.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.
- Early local immune activation following intra-operative radiotherapy in human breast tissue.